Scarily Good Deals! Save up to 30%

Shop now

L-2-Hydroxyglutaric aciduria (Discovered in the Staffordshire Bull Terrier)

L-2-Hydroxyglutaric Aciduria (L2HGA) is a metabolic disease caused by a fault in the enzyme that breaks down a chemical in the body known as L-2-hydroxyglutaric acid, which increases to toxic levels. This causes damage to the nervous system and results in incoordination, muscle stiffness during exercise or times of excitement, and altered behavior or epileptic seizures.

Key Signs

Ataxia, Muscle stiffness during exercise or excitement, Altered behavior, Epileptic seizures

Age of Onset

0 to 2 yrs

Juvenile onset

Inheritance

Autosomal Recessive

For autosomal recessive disorders, dogs with two copies of the variant are at risk of developing the condition. Dogs with one copy of the variant are considered carriers and are usually not at risk of developing the disorder. However, carriers of some complex variants grouped in this category may be associated with a low risk of developing the disorder. Individuals with one or two copies may pass the disorder-associated variant to their puppies if bred.

Likelihood of the Condition

High likelihood

At risk dogs are highly likely to show signs of this disease in their lifetime.

What to Do

Here’s how to care for a dog with L2HGA

Partner with your veterinarian to make a plan regarding your dog’s well-being, including any insights provided through genetic testing. If your pet is at risk or is showing signs of this disorder, then the first step is to speak with your veterinarian.

For Veterinarians

Here’s what a vet needs to know about L2HGA

Accumulation of L-2-hydroxyglutaric acid levels in the body leads to damage to the central nervous system in affected dogs. Typically, the disease presents itself between six months and one year of age but can present as late as seven years of age. Neurological clinical signs include ataxia, muscle stiffness during exercise or excitement, altered behavior, or epileptic seizures.

While there is no cure, palliative treatment for the clinical signs associated with the disease can improve the dog's quality of life. Seizures do generally respond to standard anti-epileptic therapy, such as phenobarbital.

For Breeders

Planning to breed a dog with this genetic variant?

There are many responsibilities to consider when breeding dogs. Regardless of test results it is important that your dog is in good general health and that you are in a position to care for the puppies if new responsible owners are not found. For first time or novice breeders, advice can be found at most kennel club websites.

This disease is autosomal recessive meaning that two copies of the mutation are needed for disease signs to occur. A carrier dog with one copy of the L2HGA mutation can be safely bred with a clear dog with no copies of the L2HGA mutation. About half of the puppies will have one copy (carriers) and half will have no copies of the L2HGA mutation. Puppies in a litter which is expected to contain carriers should be tested prior to breeding. Carrier to carrier matings are not advised as the resulting litter may contain affected puppies. Please note: It is possible that disease signs similar to the ones caused by the L2HGA mutation could develop due to a different genetic or clinical cause.

Technical Details

Gene L2HGDH
Variant T>C
Chromosome 8
Coordinate 26,723,472

All coordinates reference CanFam3.1

We’ve spent the past 20+ years devoted to DNA. Our team of scientists and vets have spent decades developing the most accurate pet DNA test. Because every pet deserves to have their whole story told. We’ve collaborated with leading academic institutions, innovative research labs, and Banfield Pet Hospital™ to make our process exceptionally precise, fast, and affordable.

References & Credit

Credit to our scientific colleagues:

Penderis, J., Calvin, J., Abramson, C., Jakobs, C., Pettitt, L., Binns, M. M., … Mellersh, C. S. (2007). L-2-hydroxyglutaric aciduria: Characterisation of the molecular defect in a spontaneous canine model. Journal of Medical Genetics, 44(5), 334–340. View the article